EİS ECZACIBAŞI İLAÇ SINAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş. Özel Durum Açıklaması (Genel) 12 Şubat 2026

An Asset Purchase Agreement was executed on 12.02.2026 (today) between our affiliated company Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi ("Gensenta/Buyer") and Sanofi Sağlık Ürünleri Ltd. Şti. (together with its subsidiaries "Sanofi/"Seller") for the transfer of 7 product registration related to 4 medicinal products for human use and trademarks (Azro, Diazomid, Furacin ve Muscoril)* to Gensenta. The assets subject to the transfer cover only the domestic market. As of today, an application has been submitted to the Turkish Competition Authority in order to obtain the required approval for the transfer transaction. Following the approval of the Competition Authority, on the last business day of the month in which the approval is granted, a total transfer price of EUR 3,000,000 and TRY 200,000,000, excluding VAT, will be paid to the Seller. The transfer of each product registration may be completed subject to obtaining the necessary approvals from the other relevant authorities.

In addition, it is planned that, by early 2029, the necessary technology transfer will be completed and the tablet and capsule dosage forms of the transferred product registrations will be manufactured by Gensenta.

*According to IQVIA data, the total value of the aforementioned products in the Turkish pharmaceutical market in 2025 is approximately EUR 7.5 million.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.